In a recent precedential opinion, the Federal Circuit rejected arguments by Amgen that a single step purification process used by Sandoz...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Amgen
-
-
On May 20, 2019, the PTAB denied a request for rehearing in Apotex Inc. v. Amgen Inc., Case IPR2016-01542 (Paper 67), but modified its...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On April 25, 2019, the U.S. Food and Drug Administration (“FDA”) approved new biosimilar product EticovoTM (etanercept-ykro) by...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Recently, in Adello Biologics LLC v. Amgen Inc., Case PGR2019-00001 (Paper No. 13) (PTAB Apr. 19, 2019), the PTAB instituted...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Over four years ago, in October 2014, Amgen initiated a patent infringement suit against Sanofi and Regeneron regarding biologics for...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On February 21, 2019, Sandoz Inc. (“Sandoz”) filed suit against Amgen Inc. and Amgen Manufacturing Limited (collectively “Amgen”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Amgen initiated suit against Apotex in the Middle District of Florida, alleging infringement of U.S. Patent No....
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, the U.S. FDA announced approval of Mylan’s Fulphila biosimilar to Neulasta® (pegfilgrastim). Neulasta® was...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On March 8, 2018, Amgen Inc. (“Amgen”) filed suit against Adello Biologics, LLC (“Adello”) in the District of New Jersey, alleging...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]